1174913-80-4

Basic information

• Product Name: (R)-2-Aminomethyl-4-boc-morpholine
• Synonyms: (R)-2-(Aminomethyl)morpholine-4-carboxylic acid tert-butyl ester;4-Morpholinecarboxylic acid, 2-(aMinoMethyl)-, 1,1-diMethylethyl ester, (2R)-;(R)-tert-butyl 2-aMinoMethylMorpholine-4-carboxylate;tert-butyl (2R)-2-(aminomethyl)morpholine-4-carboxylate;(R)-2-Aminomethyl-4-boc-morpholine;(R)-4-Boc-2-aminomethylmorpholine
• CAS NO: 1174913-80-4
• Molecular Formula: C₁₀H₂₀N₂O₃
• Molecular Weight: 216.2774
• Mol File: 1174913-80-4.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 311℃
• Flash Point: 142℃
• Appearance: /
• Density: 1.078
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 9.37±0.29(Predicted)
• CAS DataBase Reference: (R)-2-Aminomethyl-4-boc-morpholine(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-2-Aminomethyl-4-boc-morpholine(1174913-80-4)
• EPA Substance Registry System: (R)-2-Aminomethyl-4-boc-morpholine(1174913-80-4)

Safety Data

• Hazardous Substances Data: 1174913-80-4(Hazardous Substances Data)

Usage

General Description

(R)-2-Aminomethyl-4-boc-morpholine is a chemical compound with the molecular formula C9H18N2O3. It is an amino-protecting reagent used in organic synthesis to protect amino groups from unwanted reactions. The "boc" in its name stands for tert-butyloxycarbonyl, which is a protecting group frequently used in organic chemistry. (R)-2-Aminomethyl-4-boc-morpholine is frequently utilized in the preparation of peptide and nucleotide derivatives. It is also used in the production of pharmaceuticals and as an intermediate in organic synthesis. Additionally, it is known for its low toxicity and ease of handling, making it a popular choice for amino-protection in various chemical reactions.

InChI:InChI=1S/C10H20N2O3/c1-10(2,3)15-9(13)12-4-5-14-8(6-11)7-12/h8H,4-7,11H2,1-3H3/t8-/m1/s1

Upstream product

• 132073-82-6 (S)-4-Benzyl-2-(hydroxymethyl)morpholine 
• 52520-62-4 (2S)-4-benzyl-2-<<(p-tolylsulfonyl)oxy>methyl>morpholine 
• 148638-76-0 tert-butyl (2S)-2-({[(4-methylphenyl)sulfonyl]oxy}methyl)morpholine-4-carboxylate 
• 1308849-93-5 (R)-tert-butyl 2-((1,3-dioxoisoindolin-2-yl)methyl)morpholine-4-carboxylate 
• 606139-90-6 tert-butyl (2S)-2-{[(methylsulfonyl)oxy]methyl}morpholine-4-carboxylate 
• 135065-76-8 tert-butyl (2S)-2-(hydroxymethyl)morpholine-4-carboxylate 
• 1132683-15-8 tert-butyl (2S)-2-(azidomethyl)morpholine-4-carboxylate 

Downstream Products

• 1174913-72-4 tert-butyl (R)-2-((benzyloxycarbonylamino)methyl)morpholine-4-carboxylate 
• 1308849-94-6 (R)-methyl 2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-5-methyl-1H-benzo[d]imidazol-1-yl)methyl)morpholine-4-carboxylate 
• 1308849-95-7 (R)-tert-butyl 2-((2-amino-4-methylphenylamino)methyl)morpholine-4-carboxylate 
• 1308849-96-8 (R)-4-(1-((4-(tert-butoxycarbonyl)morpholin-2-yl)methyl)-5-methyl-1H-benzo[d]imidazol-2-yl)-3,5-difluorobenzoic acid 
• 1308849-97-9 (R)-tert-butyl 2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-5-methyl-lH-benzo[d]imidazol-l-yl)methyl)morpholine-4-carboxylate 
• 1308849-86-6 (S)-methyl 2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-5-methyl-1H-benzo[d]imidazol-1-yl)methyl)morpholine-4-carboxylate 
• 1308849-92-4 (S)-tert-butyl 2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-5-methyl-1H-benzo[d]imidazol-1-yl)methyl)morpholine-4-carboxylate 
• 1400589-53-8 1,1-dimethylethyl (2R)-2-{[(7-chloropyrido[3,4-b]pyrazin-5-yl)amino]methyl}-4-morpholinecarboxylate 

Relevant articles and documents

Solid dispersions containing an apoptosis-inducing agent

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

Novel Triazolopyrazine Derivatives and Use Thereof

The present invention relates to novel triazolopyrazine derivatives or a pharmaceutically acceptable salt, and a pharmaceutical composition for inhibiting c-Met tyrosine kinase activity and a pharmaceutical composition for preventing or treating hyperproliferative disorders, containing the same as active ingredients. The present invention effectively inhibits c-Met tyrosine kinase activity, thereby being able to be useful as a drug for various hyperproliferative disorders such as cancers, psoriasis, rheumatoid arthritis, diabetic retinitis, etc. related to excessive cell proliferation and growth by abnormal kinase activation.

BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS

The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.